How RAVAYA Light Grades Scientific Evidence

Scientific studies do not all provide the same level of confidence, and research involving one light-therapy device does not automatically apply to another. RAVAYA Light uses an evidence-grading framework to help readers understand:

• How a study was designed
• How reliable its findings appear to be
• Whether the study involved people, animals, tissue, or cells
• Whether the tested device resembles the RAVAYA product being discussed
• Whether the wavelength, dose, treatment area, and protocol are comparable
• What the study supports
• What the study does not establish
• How the study may be used in educational or product-related content

Our goal is not to award favorable grades to studies that support RAVAYA. Our goal is to communicate the strength, relevance, and limitations of the available evidence as clearly as possible.

What you should know

A positive study result does not automatically represent strong evidence. Small sample sizes, weak controls, incomplete reporting, short follow-up periods, selective outcomes, device differences, and inconsistent treatment protocols can all reduce confidence in a finding. RAVAYA therefore considers two related but separate questions:

• How trustworthy is the study or body of evidence?
• How directly does it apply to the RAVAYA product and claim being discussed?

A well-conducted study may still have limited relevance to RAVAYA if it examined a different device, wavelength, treatment area, dose, population, or outcome.

Important distinction: this is not the formal GRADE system

RAVAYA’s A–B–C–D–X labels are a consumer-facing editorial framework created for the RAVAYA Light Learning Center. They are not the formal GRADE ratings used in systematic reviews and clinical guidelines. The established GRADE approach evaluates certainty across a body of evidence using four levels—high, moderate, low, and very low—and considers issues including risk of bias, inconsistency, indirectness, imprecision, and publication bias. RAVAYA draws on these principles but does not claim that its simplified public labels constitute a formal GRADE assessment. When a published systematic review has performed a formal GRADE assessment, we may report that assessment separately and attribute it to the review authors.

The two parts of every RAVAYA evidence assessment

Part 1: Study quality and certainty

We evaluate whether the methods and reporting provide reasonable confidence in the result. Questions include:

• Was the research performed in humans?
• Was the study randomized?
• Was there a control or sham group?
• Were participants, assessors, or investigators blinded?
• Was the sample size adequate?
• Were outcomes defined before analysis?
• Were the outcome measures appropriate and validated?
• Was follow-up long enough for the claimed result?
• Were withdrawals and missing data reported?
• Were adverse events reported?
• Were the statistical methods appropriate?
• Were all relevant outcomes reported?
• Were funding and conflicts disclosed?
• Is the result consistent with other relevant evidence?

For randomized trials, our reviewers may consult principles from Cochrane’s RoB 2 framework, which evaluates risk of bias in specific trial results through structured domains and signaling questions. For nonrandomized intervention studies, reviewers may use relevant concepts from ROBINS-I. Reporting checklists such as CONSORT and PRISMA can help determine whether essential trial or systematic-review information has been reported transparently. They do not replace critical appraisal or risk-of-bias assessment.

Part 2: Relevance to RAVAYA

We separately evaluate whether the study can reasonably inform a statement about a current RAVAYA product. Questions include:

• Did the study test the exact RAVAYA product?
• Was the device format comparable?
• Were the same wavelengths used?
• Were wavelength bandwidth and tolerance reported?
• Was irradiance comparable?
• Was total delivered dose comparable?
• Was treatment distance comparable?
• Was the device placed against the skin or used at a distance?
• Was the same body area treated?
• Was the study population similar to the intended user?
• Was the session length comparable?
• Was the weekly frequency comparable?
• Was the measured outcome the same as the proposed claim?
• Were the findings clinically meaningful or only statistically significant?

This distinction is important because FTC guidance emphasizes that health-related substantiation must be relevant to the specific product and the specific claim. Evidence concerning a different formulation, dose, delivery method, or product may not adequately support the advertised message.

The RAVAYA evidence grades

Grade A: Direct RAVAYA evidence

Grade A is reserved for strong evidence involving the exact finished RAVAYA product or verified testing of the exact marketed model. Examples may include:

• A well-designed controlled human trial using the exact RAVAYA device
• Independent spectral testing of the exact finished product
• Independent irradiance and uniformity testing
• Battery-output stability testing
• Material or electrical testing applicable to the exact product
• Verified regulatory documentation applicable to the exact model and intended use

Grade A does not mean that every Grade A source supports every possible claim. For example:

• A spectral test can verify wavelength output.
• It cannot prove that the product reduces wrinkles.
• An electrical-safety report can support a technical safety statement.
• It cannot prove a clinical benefit.
• Regulatory clearance can establish a device’s regulatory status and cleared intended use.
• It should not be presented as universal proof that every customer will obtain a particular result.

A 510(k) clearance is based on a determination of substantial equivalence to a legally marketed predicate device. It is not the same as an independent efficacy grade assigned by RAVAYA.

Grade A requirements

To receive Grade A, the evidence must:

• Apply to the exact product or model
• Be relevant to the precise statement being made
• Use an appropriate and documented method
• Be sufficiently complete to evaluate
• Have no unresolved issue that materially undermines the conclusion
• Be reviewed by a person qualified to evaluate that form of evidence

A weak, uncontrolled RAVAYA-sponsored survey would not automatically receive Grade A merely because it involved the RAVAYA product.

Grade B: Strong comparable human evidence

Grade B applies to relatively strong human evidence involving a materially comparable device, treatment protocol, population, body area, and outcome. Examples may include:

• A randomized, sham-controlled study of a comparable home-use LED facial mask
• A high-quality systematic review of relevant human trials
• Multiple controlled human trials with reasonably consistent findings
• A study using similar wavelengths, dose, treatment geometry, and schedule

Grade B evidence may support carefully qualified category-level statements such as:

• Controlled human studies of certain red and near-infrared LED devices have reported
• improvements in some measures of facial wrinkles.

Grade B evidence would not ordinarily justify a statement such as:

• The RAVAYA mask will reduce everyone’s wrinkles by a specific percentage.

Factors that strengthen Grade B evidence

• Randomization
• Credible sham control
• Blinded outcome assessment
• Adequate sample size
• Objective or validated outcomes
• Clearly reported light parameters
• Similar facial treatment area
• Comparable device geometry
• Similar wavelength and dose
• Consistent findings across multiple studies
• Meaningful follow-up
• Transparent adverse-event reporting

Why Grade B is not Grade A

Even strong research involving another mask may differ from RAVAYA in:

• LED arrangement
• Optical output
• Treatment distance
• Facial conformity
• Coverage
• Pulse settings
• Session length
• Battery behavior
• Intended use

Those differences prevent the findings from being treated as direct RAVAYA product evidence.

Grade C: Limited, indirect, or partially comparable human evidence

Grade C includes human research that may be useful but has important limitations. Examples include:

• Small trials
• Uncontrolled studies
• Open-label studies
• Self-reported outcomes
• Short follow-up
• High participant attrition
• Poorly reported treatment parameters
• Studies with meaningful device differences
• Studies using a related but different wavelength
• Studies involving a different treatment area
• Studies with mixed or inconsistent results
• Older exploratory studies that have not been replicated

Grade C evidence may be described as:

• Preliminary
• Limited
• Emerging
• Suggestive
• In need of confirmation

It should not be described as definitive proof.

Appropriate Grade C wording

• A small human study reported improvement, but the sample size, self-reported outcomes,
• and device differences limit the certainty and applicability of the result.

Inappropriate Grade C wording

• Clinical research proves that the RAVAYA product produces this result.

A study can be scientifically interesting while remaining unsuitable for a strong product claim.

Grade D: Preclinical or mechanistic evidence

Grade D includes research that does not directly evaluate a consumer outcome in living human participants. Examples include:

• Cell-culture studies
• Fibroblast studies
• Tissue studies
• Ex vivo skin studies
• Animal studies
• Biochemical pathway studies
• Computer modeling
• Proposed biological mechanisms

Grade D evidence can help explain:

• Possible photoacceptors
• Mitochondrial signaling
• Cellular pathways
• Collagen-related laboratory markers
• Inflammatory signaling
• Dose-response hypotheses
• Optical behavior in tissue

It cannot, by itself, prove that a consumer device:

• Reduces visible wrinkles
• Clears acne
• Improves pigmentation
• Lifts the face
• Sculpts the jawline
• Produces a particular clinical result
• Is safe for every user

Required Grade D disclosure

When Grade D research is discussed, the article should clearly identify it as laboratory, tissue, animal, or mechanistic evidence. Readers should not have to infer that distinction from the citation.

Grade X: Not applicable to the current product or claim

Grade X means the research may be legitimate but is not suitable for supporting the current RAVAYA mask or the particular claim being evaluated. Examples include:

• High-powered surgical or dermatologic lasers
• Transcranial photobiomodulation
• Full-body panel research
• Scalp hair-growth devices
• Oral or dental applications
• Wound-treatment protocols
• Research involving unrelated medical diseases
• Studies using substantially different wavelengths
• Studies with incomparable energy levels
• Studies involving a different body area
• Photodynamic therapy requiring a photosensitizing drug
• Research where the measured outcome does not match the proposed claim

Grade X does not mean the study is poor quality. A rigorous randomized trial of transcranial light therapy may be scientifically strong while having no meaningful relevance to a facial skincare mask.

Grade X use

Grade X studies may appear in a clearly separated broader PBM research archive when they help readers understand the field. They should not be used to imply that the current RAVAYA facial mask treats the condition or reproduces the studied outcome.

Evidence-grade summary

RAVAYA’s study-to-product transferability score

In addition to the public evidence grade, RAVAYA may assign a study-to-product transferability score. The score helps reviewers evaluate how closely a study resembles the RAVAYA product and intended statement. Eight areas are assessed from 0 to 2 points.

1. Population match

• 0: Nonhuman or substantially unrelated population
• 1: Human population with meaningful differences
• 2: Population reasonably similar to intended RAVAYA users

2. Treatment-area match

• 0: Unrelated body area
• 1: Skin research on a different area
• 2: Face, periocular area, or the exact intended treatment area

3. Device and delivery match

• 0: Materially different technology, such as a high-powered laser
• 1: LED device with meaningful geometric or delivery differences
• 2: Materially comparable home-use facial-mask format

4. Wavelength match

• 0: No meaningful wavelength match
• 1: Partial, adjacent, or incompletely reported match
• 2: Same relevant wavelength range

5. Irradiance and dose match

• 0: Unknown or substantially different
• 1: Partially comparable
• 2: Measured and reasonably comparable

6. Schedule match

• 0: Materially different session length or frequency
• 1: Partially comparable
• 2: Similar duration, frequency, and total treatment period

7. Outcome match

• 0: Unrelated outcome
• 1: Related surrogate or subjective outcome
• 2: Directly relevant and appropriately measured consumer outcome

8. Design quality

• 0: Mechanistic, preclinical, or seriously limited
• 1: Human research with meaningful limitations
• 2: Strong controlled research or a rigorous evidence synthesis

Score interpretation

• Score
• Interpretation
• 13–16
• High transferability
• 9–12
• Moderate transferability
• 5–8
• Low transferability
• 0–4
• Not suitable for supporting a RAVAYA product claim

A high transferability score does not convert another company’s study into RAVAYA-specific evidence. It means the study may be especially useful for qualified category-level education.

How systematic reviews and meta-analyses are evaluated

A systematic review is not automatically strong evidence simply because it combines multiple studies. We evaluate:

• Whether the research question was clearly defined
• Whether the search was sufficiently comprehensive
• Whether inclusion criteria were stated
• Whether excluded studies were accounted for
• Whether study quality or risk of bias was assessed
• Whether devices and protocols were sufficiently comparable
• Whether statistical pooling was appropriate
• Whether heterogeneity was investigated
• Whether publication bias was considered
• Whether conclusions matched the underlying evidence
• Whether the review followed transparent reporting practices

PRISMA provides reporting guidance for systematic reviews, including checklists and flow diagrams intended to improve the completeness and transparency of reporting. A PRISMA-compliant report can still contain weak underlying studies or substantial indirectness, so reporting completeness is evaluated separately from certainty. When a meta-analysis pools very different devices, wavelengths, doses, outcomes, or populations, its average result may have limited relevance to a specific consumer device.

A study’s result direction does not determine its grade

RAVAYA does not grade studies according to whether the result is favorable. A well-designed study with a null result may receive a stronger methodological assessment than a poorly designed study reporting a large benefit. Study records may therefore be labeled:

• Positive
• Mixed
• Null
• Negative
• Inconclusive

These labels describe the direction of the reported findings. They do not describe study quality. We seek to include relevant contradictory and null findings rather than presenting only favorable research. FTC guidance stresses that substantiation should be considered in light of the entire body of relevant evidence, including evidence that conflicts with the proposed claim.

Statistical significance is not the same as practical importance

A statistically significant result is not automatically large, visible, or meaningful to a user. When possible, we examine:

• Absolute change
• Relative change
• Confidence intervals
• Effect size
• Baseline severity
• Measurement method
• Clinical or practical relevance
• Participant perception
• Durability of the result

An article should not convert a small change in a technical measurement into a claim of dramatic visible transformation without sufficient support.

How sample size affects our assessment

A small study is not automatically invalid, but small samples generally provide less precise estimates and are more vulnerable to chance imbalances and unstable results. We consider:

• Number enrolled
• Number randomized
• Number completing treatment
• Number included in analysis
• Reasons for withdrawal
• Whether a sample-size calculation was reported
• Whether the analysis accounted for missing data

A report stating that “most participants improved” may be misleading when only a small number of people completed the study.

How we evaluate subjective outcomes

Some skincare outcomes are inherently subjective. Participant satisfaction and blinded expert grading can still provide useful information. We assess:

• Whether the scale was validated
• Whether baseline and follow-up images were standardized
• Whether graders were blinded
• Whether lighting and camera conditions were controlled
• Whether participants knew which treatment they received
• Whether the outcome was defined before analysis
• Whether objective measures supported the subjective result

Self-reported improvement is presented as self-reported improvement—not as an independently measured clinical effect.

How funding and conflicts affect grading

Industry funding does not automatically invalidate a study. However, readers should know when:

• A manufacturer funded the study
• Authors were employees or consultants
• The device was supplied by the manufacturer
• The sponsor controlled data analysis
• The sponsor participated in writing
• Investigators held patents or financial interests
• The role of the sponsor was not reported

Funding and conflicts are considered alongside study design, reporting, replication, and consistency with independent evidence. When known, these relationships should appear on the study card.

How regulatory evidence is handled

Regulatory documentation is evaluated separately from clinical research. A public FDA record may establish:

• Device identity
• Applicant or manufacturer
• Regulatory pathway
• Predicate device
• Intended use
• Clearance date

It does not automatically establish:

• Superiority over competing products
• Effectiveness for an uncleared use
• Identical performance across modified models
• A guaranteed consumer outcome

The FDA describes the 510(k) pathway as a comparison with a legally marketed predicate to establish substantial equivalence. RAVAYA therefore reports regulatory status separately from its editorial evidence grade.

How evidence grades affect article wording

Grade A wording

May support a product-specific statement when the evidence directly measures the claimed characteristic or outcome. Example:

• Independent testing of the exact finished RAVAYA model measured spectral output at the
• stated wavelength range.

The report, method, product version, laboratory, date, and limitations should be available.

Grade B wording

Supports qualified category-level statements. Example:

• Controlled studies of certain home-use red and near-infrared LED masks have reported
• improvement in some facial-wrinkle measures.

The article must state when RAVAYA was not the tested device.

Grade C wording

Requires visible qualification. Example:

• Preliminary human research suggests a possible effect, but the small sample and device
• differences prevent a firm conclusion.

Grade D wording

Limited to mechanism or research background. Example:

• Laboratory research has identified possible cellular pathways, but these findings do not
• establish a visible result in people.

Grade X wording

Must not be used as product substantiation. Example:

• This research involved a different device, treatment area, and indication and does not
• establish an outcome for the RAVAYA facial mask.

Claims that require special scrutiny

The following claim categories generally require stronger and more direct evidence:

• Treating acne
• Preventing or treating a disease
• Post-surgical recovery
• Wound healing
• Reducing inflammation
• Changing pigmentation
• Treating melasma or rosacea
• Eye safety
• Use during pregnancy
• Use with medications
• Lifting facial muscles
• Sculpting the jawline
• Stimulating lymphatic drainage
• Producing results equivalent to a professional procedure
• Guaranteed result percentages
• Guaranteed result timelines

The stronger and more specific the claim, the more direct and reliable the supporting evidence must be. FTC guidance states that the required level of substantiation depends on the nature and specificity of the claim and the consequences of a false claim.

How evidence grades appear in the RAVAYA library

Evidence-led articles may display a badge near the article header. The badge should link to this methodology page. Example: Evidence grade: B — Strong comparable human evidence Study cards may show:

• Evidence grade
• Study type
• Human or preclinical classification
• Risk-of-bias summary
• Result direction
• Transferability score
• RAVAYA relevance
• Date reviewed

Articles drawing from several evidence levels should not be assigned the grade of their strongest citation alone. The displayed article grade should reflect the overall body of evidence supporting the article’s central conclusion.

Evidence-review workflow

Each significant scientific resource should pass through the following process.

1. Define the question

Specify:

• Population
• Device or intervention
• Comparator
• Outcome
• Treatment period
• Product or category relevance

2. Locate relevant research

Prioritize:

• Systematic reviews
• Controlled human trials
• Applicable regulatory records
• Exact-product testing
• Relevant safety evidence

3. Verify the source

Confirm:

• Correct study identity
• Authors
• Journal
• Publication year
• PMID or DOI
• Full text where accessible
• Correction or retraction status

4. Extract the study details

Record:

• Design
• Sample
• Device
• Wavelength
• Irradiance
• Fluence
• Schedule
• Comparator
• Outcomes
• Adverse events
• Limitations
• Funding
• Conflicts

5. Assess quality

Evaluate risk of bias, reporting completeness, precision, consistency, and possible selective reporting.

6. Assess RAVAYA relevance

Complete the transferability assessment and determine whether the evidence is direct, comparable, indirect, mechanistic, or inapplicable.

7. Draft permitted wording

The conclusion must not extend beyond what the evidence reasonably supports.

8. Obtain appropriate review

Depending on the topic, review may involve:

• Dermatology
• Pharmacology
• Ophthalmology
• Regulatory affairs
• Optical engineering
• Electrical engineering
• Product quality
• Statistics

9. Publish limitations with the conclusion

Limitations should be easy to find and understand. They should not be hidden only in a reference list or disclaimer.

10. Assign a review date

The evidence should be reviewed again when:

• Important new research is published
• A source is corrected or retracted
• Product specifications change
• Regulatory status changes
• A material concern is reported

Corrections and grade changes

Evidence grades may change over time. A grade may be upgraded when:

• Larger controlled trials become available
• Independent replication supports the result
• Better product-specific testing is completed
• Reporting gaps are resolved
• A rigorous synthesis strengthens confidence

A grade may be downgraded when:

• New studies conflict with earlier findings
• A source is corrected or retracted
• Undisclosed conflicts are discovered
• Study methods are found to be weaker than initially understood
• The RAVAYA product changes
• The proposed claim expands beyond the evidence

Material changes should be documented in the page’s revision history. Possible errors or missing studies may be reported through the RAVAYA Light contact page.

Limitations of the RAVAYA framework

No evidence-grading system can eliminate judgment. Two qualified reviewers may reasonably differ about:

• Risk of bias
• Clinical significance
• Device comparability
• The importance of a limitation
• Whether evidence is sufficiently consistent
• Whether an outcome is meaningful to consumers

The RAVAYA framework is intended to make those judgments more transparent. It is not a substitute for a formal systematic review, regulatory evaluation, clinical guideline, or personalized medical advice.

Frequently asked questions

Does Grade A guarantee a result?

No. Grade A means the evidence directly applies to the exact RAVAYA product or verified product characteristic and is sufficiently strong for the limited statement being made. It does not mean every user will experience the same result.

Can an animal study ever receive Grade A?

No. Animal and laboratory research is classified as Grade D within this consumer-facing framework, even when the study itself is rigorous.

Is a randomized trial always Grade B?

No. A randomized trial may receive Grade C when it is too small, poorly reported, at high risk of bias, materially different from RAVAYA, or otherwise unable to support a strong conclusion.

Is a systematic review always stronger than one trial?

Not necessarily. A systematic review may combine weak, highly inconsistent, or materially different studies. We evaluate the review methods and the underlying evidence.

Does using the same wavelength make two devices comparable?

No. Devices may differ in irradiance, dose, pulse behavior, distance, coverage, treatment time, uniformity, and intended use.

Can a Grade D study be cited?

Yes, when it is clearly identified as mechanistic or preclinical and is not presented as proof of a human consumer result.

What does Grade X mean?

Grade X means the study does not apply to the current product or claim. It does not necessarily mean the study is scientifically poor.

Can RAVAYA change a grade?

Yes. Grades may change as evidence, product specifications, or regulatory information changes. Material revisions should be recorded.

Related RAVAYA resources

Once published, link this page to:

• RAVAYA Light Editorial and Medical Review Policy
• RAVAYA Photobiomodulation Research Library
• RAVAYA Testing and Transparency Center
• Complete Guide to At-Home LED Light Therapy
• LED Light Therapy Safety and Suitability
• How Photobiomodulation Works

Do not activate links to pages that have not yet been published.

Methodology history

Effective: July 30, 2026 Last updated: July 30, 2026 Current version: 1.0 Material changes to grading definitions, transferability scoring, or review requirements will be recorded here.

Selected methodology references

• GRADE Working Group. Overview and principles for assessing certainty of evidence.
• Cochrane. GRADE and certainty-of-evidence guidance.
• Cochrane. RoB 2 risk-of-bias tool for randomized trials.
• Cochrane. ROBINS-I for nonrandomized intervention studies.
• CONSORT. Updated guidance for transparent reporting of randomized trials.
• PRISMA. Reporting guidance for systematic reviews.
• Federal Trade Commission. Health Products Compliance Guidance.
• U.S. Food and Drug Administration. 510(k) and substantial-equivalence guidance.

Educational-use statement

This methodology describes RAVAYA Light’s editorial review process. It is not a clinical guideline, regulatory determination, formal GRADE assessment, or substitute for evaluation by a qualified healthcare, scientific, engineering, or regulatory professional.